25-04-2024 01:16 via rocketnews.com

Acrivon Therapeutics’ shares climb 14% on plans to present cancer-test data

Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnShares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with
Read more »

Analyst news



Credit cards are the ‘financing of last resort’ for older adults as inflation persists
Personal-finance guru Dave Ramsey says it’s a great time to buy a house. Experts don’t agree.
U.S. stocks rally on ‘Goldilocks’ jobs report as Wall Street’s fear gauge slides
Luminar’s stock falls as lidar maker plans to lay off 20% of workforce as part of restructuring plan
Nasdaq finally ‘warming up’ to Canadian cannabis companies with U.S. exposure. Could American growers be next?
‘He’s holding all the cards’: My mother, 86, has dementia. Her partner of 30 years is on the deed to her home. How can I gain control of her finances?
Treasury yields see biggest weekly drops in months as tepid April jobs report raises rate-cut hopes
Cocoa futures turn bitter as prices drop 30% from record highs
Same job, $16 less per hour: Frustrated job hunters can’t find roles that pay as well as their old ones
FuboTV’s stock dives as excessively high licensing costs led to loss of content
Fed still trying to assess if recent hot inflation readings mean economy is ‘overheating,’ Goolsbee says
SEC charges firm that audits Trump’s Truth Social with ‘massive fraud’ affecting hundreds of filings
FuboTV’s stock surges after losses narrow to half what was expected
Pat Gelsinger was brought in to fix Intel. 3 years later, it still seems like a mess.
Desktop versie